• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

    43.18 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Agios Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tops Q3 2025 Estimates with Strong Revenue Beat
    Agios Pharma's Q3 2025 results beat revenue and EPS estimates, driving a positive market reaction and highlighting strong commercial performance. 
    Via Chartmill
    Earnings Scheduled For October 30, 2025
     
    Via Benzinga
    Earnings Outlook For Agios Pharmaceuticals
     
    Via Benzinga
    Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
    San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
    Via MarketMinute
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns
    Via Stocktwits
    Earnings Scheduled For July 31, 2025
     
    Via Benzinga
    Earnings Scheduled For May 1, 2025
     
    Via Benzinga
    An Overview of Agios Pharmaceuticals's Earnings
     
    Via Benzinga
    Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
    While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 
    Via Stocktwits
    FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use
    Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury risk. 
    Via Benzinga
    Top movers in Thursday's pre-market session
    As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
    Via Chartmill
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    Earnings Scheduled For February 13, 2025
     
    Via Benzinga
    Analyst Ratings For Agios Pharmaceuticals
     
    Via Benzinga
    Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
     
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
     
    Via Benzinga
    Traders are paying attention to the gapping stocks in Monday's session.
    Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
    Via Chartmill
    What's going on in today's pre-market session
    As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    Earnings Preview: Agios Pharmaceuticals
     
    Via Benzinga
    4 Analysts Have This To Say About Agios Pharmaceuticals
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Agios (AGIO) Q2 Revenue Jumps 45%
    Via The Motley Fool
    Topics Intellectual Property
    Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss
    Agios Pharmaceuticals (AGIO) reported Q2 2025 revenue of $12.46M, beating estimates, but EPS of -$1.93 missed forecasts. Shares fell 10.66% pre-market amid mixed financials and ongoing rare disease... 
    Via Chartmill
    Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
    Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results. 
    Via Benzinga
    Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
    The company is currently seeking approval for its thalassemia treatment in four regions. 
    Via Investor's Business Daily
    This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
     
    Via Benzinga
    Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
     
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.